Down 39% in 3 months while the S&P 500 was flat.
−2Long-term trend
LXRX's Quality Score rose 2 points on Mon, Nov 2, to -4.
Follow LXRX's trial news. Pro members can get an alert when Lexicon Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Sales down 29% on the year |
| Latest filing | 10-Q, Aug 6 |
ReportReports Thursday, before the open. Every 3 months, a company tells everyone how much it sold and earned. It rose after 3 of its last 4 reports, +1.4% on average. Past reports ›
After its last 4 reports it closed +1.4% on average, higher 3 of 4 times.
About 11 quarters
Director Raymond Debbane bought 2,000 shares on Feb 25. 4 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
LXRX is #201 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 201 |
Share count against a year before: LXRX +20%, ACHV +170%, BHVN +47%, OCUL +30%.
Reports Thu Nov 5, before the open (in 3 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“Research and development expenses for the second quarter of 2026 increased to $17.4 million from $15.7 million for the corresponding period in 2025, reflecting higher external research expense in 2026 related to the Company’s ongoing SONATA-HCM Phase 3 clinical trial.”
LXRX's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
Sales fell 9.1% a year over 10 years, fiscal 2015 to 2025.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 6, 2026 | -20.0% | -3.7% | -4.1% |
| May 7, 2026 | +3.1% | +5.0% | +52.5% |
| Mar 5, 2026 | -5.5% | +0.6% | +5.5% |
Sales grew in four of the last seven years, to $49.8M in 2025. It made a profit in one of the eight years.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: LXRX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
“The biotechnology and pharmaceutical industries are highly competitive and characterized by rapid technological change.”
LXRX scores -4 today, which Breakaway calls Poor. It is #201 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 39% in 3 months while the S&P 500 was flat. Cash lasts about 11 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
LXRX scores -4 today, which Breakaway calls Poor (below zero). That is #201 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind LXRX's -4.
Reports Thu Nov 5, before the open, a date the company confirmed. LXRX closed higher after 3 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.